Sabra Health Care REIT (SBRA) to Release Earnings on Thursday

Sabra Health Care REIT (NASDAQ:SBRA - Get Free Report) will announce its earnings results after the market closes on Thursday, October 31st. Analysts expect the company to announce earnings of $0.35 per share for the quarter. Sabra Health Care REIT has set its FY24 guidance at $1.39-1.42 EPS and its FY 2024 guidance at 1.360-1.390 EPS.Investors interested in registering for the company's conference call can do so using this link.

Sabra Health Care REIT (NASDAQ:SBRA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The real estate investment trust reported $0.10 earnings per share for the quarter, missing analysts' consensus estimates of $0.34 by ($0.24). The company had revenue of $176.14 million for the quarter, compared to the consensus estimate of $166.54 million. Sabra Health Care REIT had a net margin of 7.83% and a return on equity of 1.87%. Sabra Health Care REIT's revenue for the quarter was up 9.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.34 earnings per share. On average, analysts expect Sabra Health Care REIT to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sabra Health Care REIT Price Performance

SBRA traded up $0.02 on Thursday, reaching $19.01. The company had a trading volume of 1,780,187 shares, compared to its average volume of 2,019,660. The company has a market capitalization of $4.40 billion, a P/E ratio of 95.05, a PEG ratio of 2.68 and a beta of 1.26. The company has a current ratio of 4.27, a quick ratio of 4.27 and a debt-to-equity ratio of 0.89. The company has a fifty day moving average of $17.87 and a 200-day moving average of $15.96. Sabra Health Care REIT has a one year low of $12.83 and a one year high of $19.32.

Sabra Health Care REIT Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 30th. Investors of record on Monday, August 19th were paid a dividend of $0.30 per share. The ex-dividend date of this dividend was Monday, August 19th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 6.31%. Sabra Health Care REIT's dividend payout ratio is presently 600.00%.

Analysts Set New Price Targets

SBRA has been the subject of a number of research analyst reports. Wells Fargo & Company upgraded Sabra Health Care REIT from an "equal weight" rating to an "overweight" rating and upped their target price for the stock from $16.00 to $20.00 in a research report on Tuesday, October 1st. Citigroup upgraded Sabra Health Care REIT from a "neutral" rating to a "buy" rating and upped their price objective for the company from $17.00 to $20.00 in a report on Friday, September 13th. Scotiabank lifted their target price on Sabra Health Care REIT from $17.00 to $18.00 and gave the stock a "sector perform" rating in a report on Friday, October 11th. Finally, Truist Financial boosted their price target on shares of Sabra Health Care REIT from $16.00 to $18.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $18.38.

About Sabra Health Care REIT

As of September 30, 2023, Sabra's investment portfolio included 377 real estate properties held for investment (consisting of (i) 240 Skilled Nursing/Transitional Care facilities, (ii) 43 senior housing communities (Senior Housing - Leased), (iii) 61 senior housing communities operated by third-party property managers pursuant to property management agreements (Senior Housing - Managed), (iv) 18 Behavioral Health facilities and (v) 15 Specialty Hospitals and Other facilities), 12 investments in loans receivable (consisting of two mortgage loans and 10 other loans), five preferred equity investments and two investments in unconsolidated joint ventures.